



SUVEN PHARMACEUTICALS LTD

Regd. Off: 3rd Floor ,SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UNAUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31,2023

PART - I		STANDALONE					Rs.in Lakhs
Sl. No.	PARTICULARS	For the Quarter Ended			For 9 Months Ended		For the Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	Income						
	Revenue from operations	21,282.67	22,462.13	34,848.90	78,147.36	96,568.99	1,33,007.98
	Other Income	1,396.81	1,420.02	1,251.05	3,822.73	3,379.74	4,455.20
	Total income	22,679.48	23,882.15	36,099.95	81,970.09	99,948.73	1,37,463.18
2	Expenses						
	a) Cost of materials consumed	6,065.24	4,694.69	13,516.42	18,522.29	33,179.49	42,136.24
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	638.78	897.29	(2,650.99)	3,686.05	(4,182.10)	(2,094.42)
	c) Manufacturing Expenses	3,118.12	2,778.51	4,599.26	9,006.94	13,187.47	17,087.35
	d) Employee benefits expense	3,061.71	2,651.34	2,726.37	8,340.06	7,794.32	10,084.31
	e) R & D expense	228.22	447.39	226.99	884.41	657.68	858.57
	f) Finance costs	126.90	50.28	137.94	291.83	310.22	539.17
	g) Depreciation and amortisation expenses	1,133.37	1,048.10	1,091.38	3,296.24	3,221.73	4,284.46
	h) Other Expenses	1,356.97	1,257.52	1,724.14	4,170.40	5,087.18	6,628.17
	Total expenses	15,729.31	13,825.12	21,371.51	48,198.22	59,255.99	79,523.85
3	Profit before exceptional items & Tax (1-2)	6,950.17	10,057.03	14,728.44	33,771.87	40,692.74	57,939.33
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	6,950.17	10,057.03	14,728.44	33,771.87	40,692.74	57,939.33
6	Tax Expenses						
	a) Current tax	1,384.98	2,429.26	3,715.23	7,945.31	10,165.80	14,462.56
	b) Deferred tax	406.45	155.16	66.59	765.86	282.87	433.75
	c) Prior year tax	(77.64)	-	-	(77.64)	-	(217.23)
7	Net Profit/ (Loss) for the period/year(5-6)	5,236.38	7,472.61	10,946.62	25,138.34	30,244.07	43,260.25
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(112.92)	-	(25.48)	(111.71)	(76.45)	(35.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	28.42	-	6.41	28.12	19.24	8.85
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(84.50)	-	(19.07)	(83.59)	(57.21)	(26.31)
9	Total Comprehensive Income for the period (7+8)	5,151.88	7,472.61	10,927.55	25,054.75	30,186.86	43,233.94
10	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity						1,72,392.41
12	Earning Per Share (EPS)-Face value of Rs.1/- each)						
	a) Basic	2.06	2.94	4.30	9.88	11.88	16.99
	b) Diluted	2.06	2.94	4.30	9.88	11.88	16.99
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



PART - II		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For 9 Months Ended		For the Year Ended
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	31-03-2023
		UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
1	Income						
	Revenue from operations	21,981.96	23,105.37	35,377.17	79,842.34	97,097.26	1,34,032.88
	Other Income	1,434.46	1,984.17	1,301.12	4,485.14	3,496.43	4,636.38
	Total income	23,416.42	25,089.54	36,678.29	84,327.48	1,00,593.69	1,38,669.26
2	Expenses						
	a) Cost of materials consumed	6,352.59	5,115.60	13,603.62	19,445.37	33,452.18	43,007.88
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	891.34	644.73	(2,639.91)	3,686.05	(4,182.11)	(2,094.42)
	c) Manufacturing Expenses	3,270.26	2,927.86	4,736.40	9,425.65	13,582.17	17,628.79
	d) Employee benefits expense	3,283.25	2,857.68	2,967.54	9,015.33	8,490.88	11,051.09
	e) R & D expense	228.22	447.39	226.98	884.41	657.67	858.57
	f) Finance costs	126.90	50.28	138.27	291.83	312.77	543.63
	g) Depreciation and amortisation expense	1,275.18	1,189.19	1,223.90	3,718.49	3,577.41	4,773.24
	h) Other Expenses	1,441.85	1,315.98	1,813.06	4,378.38	5,350.83	6,927.50
	Total expenses	16,869.59	14,548.71	22,069.86	50,845.51	61,241.80	82,696.28
3	Profit before exceptional items , Tax & share in profit/(Loss) of Associates (1-2)	6,546.83	10,540.83	14,608.43	33,481.97	39,351.89	55,972.98
4	Add : Share of profit/(Loss) of Associates.	-	-	-	-	-	-
5	Profit before exceptional items , Tax (3+4)	6,546.83	10,540.83	14,608.43	33,481.97	39,351.89	55,972.98
6	Exceptional Items	-	-	-	-	-	-
7	Profit before Tax (5-6)	6,546.83	10,540.83	14,608.43	33,481.97	39,351.89	55,972.98
8	Tax Expenses						
	a) Current tax	1,542.67	2,429.26	3,769.77	8,103.00	10,337.11	14,627.43
	b) Deferred tax	406.45	155.16	66.60	765.86	282.88	433.75
	c) Prior year tax	(77.64)	-	-	(77.64)	-	(217.23)
9	Net Profit/ (Loss) for the period/year(7-8)	4,675.35	7,956.41	10,772.06	24,690.75	28,731.90	41,129.03
10	Other Comprehensive Income						
10.a	(i) Items that will not be reclassified to profit or loss	(112.92)	-	(25.60)	(111.71)	(76.77)	(27.49)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	28.41	-	6.41	28.11	19.24	8.85
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(84.51)	-	(19.19)	(83.60)	(57.53)	(18.64)
11	Total Comprehensive Income for the period (9 + 10)	4,590.84	7,956.41	10,752.87	24,607.15	28,674.37	41,110.39
12	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
13	Other Equity						1,70,972.78
14	Earning Per Share (EPS)- (Face value of Rs.1/- each)						
	a) Basic -	1.84	3.13	4.23	9.70	11.29	16.16
	b) Diluted	1.84	3.13	4.23	9.70	11.29	16.16
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 5th February 2024. Results for the quarter ended 31st December, 2023 have been reviewed by our statutory auditors.
 - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
 - 3) The consolidated financial results include the results of the wholly owned subsidiaries Suvan Pharma, Inc., USA & Casper Pharma Pvt Ltd.
 - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
 - 5) As per share purchase agreement dated 26th December 2022 entered into by and between Berhyanda Limited (Buyer), Jasti Property and Equity Holdings private limited (in their capacity as sole trustee of Jasti Family Trust) (Seller) and Mr. Venkatesearlu Jasti (Seller representative) pursuant to SEBI SAST Regulations, 2011 as amended, M/s Berhyanda Limited, a Cyprus based company and an investment arm of Adven International Corporation, USA has acquired controlling stake to the tune of 11,75,37,043 equity shares aggregating to 50.10% in the company on 29th September, 2023 from the seller.
 - 6) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

For SUVEN PHARMACEUTICALS LTD



mcp abgjf
Dr.V. PRASADA RAJU
Managing Director
DIN: 07267366

Place : Hyderabad

Date : 5th February ' 2024